14 filings
8-K
APLT
Applied Therapeutics Inc
13 Nov 19
Applied Therapeutics Reports Third Quarter 2019 Financial Results
7:15am
8-K
APLT
Applied Therapeutics Inc
12 Nov 19
Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock
9:24am
8-K
APLT
Applied Therapeutics Inc
4 Sep 19
Departure of Directors or Certain Officers
5:06pm
8-K
APLT
Applied Therapeutics Inc
4 Sep 19
Other Events
8:00am
8-K
APLT
Applied Therapeutics Inc
12 Aug 19
Applied Therapeutics Reports Second Quarter 2019 Financial Results
7:16am
8-K
oj6ku
8 Aug 19
Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study
7:00am
8-K
f82kfnpooc hnfdldhv
6 Aug 19
Regulation FD Disclosure
8:10am
8-K
3ks00 1gawj
24 Jun 19
Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 In Galactosemia
7:09am
8-K
9pbaf23 qa
21 Jun 19
Applied Therapeutics Reports First Quarter 2019 Financial Results
7:34am
8-K
g14am
7 Jun 19
AT-001, a novel, potent and selective aldose reductase inhibitor, is expected to start a pivotal study later this year
7:59am
8-K
bay5xf3o1mdv35s5pu2
6 Jun 19
Departure of Directors or Certain Officers
4:05pm
8-K
v8evwdvrr
28 May 19
Applied Therapeutics Announces Fda Orphan Drug Designation for AT-007 In Galactosemia
5:14pm
8-K
cb9g6
24 May 19
Other Events
4:24pm
8-K
ypaqokg67gab37nntv
16 May 19
Amendments to Articles of Incorporation or Bylaws
5:22pm
- Prev
- 1
- Next